Sun Pharmaceutical Industries announced it would buy 100% of Innovcare Lifesciences in an all-cash deal valued at about ₹271.2 crore, or $28.73 million. The acquisition is being positioned as a portfolio-building move.
Innovcare Lifesciences is a Mumbai-based company that markets, distributes and sells pharmaceutical drugs, nutraceuticals and cosmeceutical products.
Innovcare reported revenue from operations of ₹94.06 crore in FY26, compared with ₹86.09 crore in FY25 and ₹80.93 crore in FY24, according to Outlook Business.
Sun Pharma is acquiring Innovcare to add products, channels and category reach in India, where the company is already large. Sun Pharma described the move as a strategic investment to strengthen the company’s product portfolio.
The transaction does not constitute a related-party deal, as neither Sun Pharma’s promoters nor promoter group entities have an interest in Innovcare, and no government or regulatory approvals are required for the transaction. That makes the path to closing comparatively straightforward.
This Innovcare transaction is modest when set against Sun Pharma’s much larger $11.75 billion Organon deal.
The deal comes at a time when Sun Pharma is already active on the acquisition front. In that context, Innovcare looks less like a standalone headline and more like part of a broader capital-allocation pattern: buy assets that fit the product stack, improve distribution density and fill category gaps without disturbing the balance sheet with a transformational price tag. That reading is an inference from the two transactions reported in the same period.
Key numbers
| Acquirer | Sun Pharmaceutical Industries |
| Target | Innovcare Lifesciences Pvt. Ltd. |
| Deal type | 100% acquisition, all-cash |
| Deal value | ₹271.2 crore |
| USD equivalent | $28.73 million |
| Announcement date | June 20, 2026 |
| Expected closing | On or before July 31, 2026 |
| Innovcare FY26 revenue | ₹94.06 crore |
| Business focus | Pharma, nutraceuticals, cosmeceuticals |
Sun Pharma Innovcare acquisition will strengthen the company’s product portfolio, add a domestic business with reported revenue of ₹94.06 crore in FY26, and close the gap between distribution strength and product breadth.
[ALSO READ: Akums Pharma’s Finance Chief Rajkumar Bafna Resigns Citing Pollution in Delhi]
